Biosimilars: Patient and Physician Acceptability is the Fifth Hurdle to Market Competition

dc.contributor.author	Lyles, Alan
dc.date.accessioned	2018-04-03T17:18:51Z
dc.date.available	2018-04-03T17:18:51Z
dc.date.issued	2015
dc.description.abstract	Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.	en_US
dc.format.extent	2 pages	en_US
dc.genre	journal articles	en_US
dc.identifier	doi:10.13016/M2NG4GT6B
dc.identifier.citation	Lyles, A., (2015). Biosimilars: Patient and Physician Acceptability is the Fifth Hurdle to Market Competition. Generics and Biosimilars Initiative Journal. 4(1). DOI: 10.5639/gabij.2015.0401.002.	en_US
dc.identifier.uri	http://hdl.handle.net/11603/7906
dc.language.iso	en_US	en_US
dc.publisher	GaBi Journal (Generics and Biosimilars Initiative Journal	en_US
dc.relation.isAvailableAt	University of Baltimore
dc.subject	acceptability	en_US
dc.subject	Biologicals	en_US
dc.subject	Biosimilars	en_US
dc.subject	interchangeability	en_US
dc.subject	pricing	en_US
dc.title	Biosimilars: Patient and Physician Acceptability is the Fifth Hurdle to Market Competition	en_US
dc.type	Text	en_US

Files

Now showing 1 - 1 of 1

Name:: Biosimilars- patient and physician acceptability is the fifth hurdle to market competition - GaBI Journal.pdf
Size:: 88.17 KB
Format:: Adobe Portable Document Format
Description:

Now showing 1 - 1 of 1